Search clinical trials for: Vidaza®

Total 13957 results

BioMérieux

Completed

Impact of Differential and Systematic Diagnosis of Dengue, Chikungunya and Malaria on Patient Management and Antibiotic Use in West Africa

Malaria | Dengue | Chikungunya

Burkina Faso, Côte D'Ivoire
ConvaTec Inc.

Completed

Multi-National Phase III Vitala™ 12-Hour Wear Test

Colostomy

United States, United Kingdom, Germany
BioMérieux

Completed

VIDAS Nephroclear (NCL) CCL14 - Sample Stability

Acute Kidney Injury

United States
BioMérieux

Completed

VIDAS® NEPHROCLEAR Diagnostic Accuracy Study

Acute Kidney Injury | Stage 2 Acute Kidney Injury | Stage 3 Acute Kidney Injury

United States
Sun Yat-sen University

Recruiting

Sintilimab in Combination With Chidamide in Newly Diagnosed ENKTCL

Safety and Efficacy

China
Sun Yat-sen University

Not yet recruiting

Sintilimab in Combination With Chidamide in Refractory and Relapsed AITL

Angioimmunoblastic T-cell Lymphoma

China
Huiqiang Huang

Completed

Sintilimab in Combination With Chidamide in Refractory and Relapsed ENKTCL

Safety and Efficacy

China
Technische Universität Dresden

Completed

Treatment of Patients With Myelodysplastic Syndrome or Acute Myelocytic Leukemia With an Impending Hematological Relapse With Azacitidine (Vidaza) (RELAZA2)

Myelodysplastic Syndrome | Acute Myelocytic Leukemia

Germany
Celgene

Completed

Post Marketing Surveillance to Collect and Evaluate the Safety and Efficacy Information of Korean MDS Patients Treated With VIDAZA®, After Approval of Marketing Authorization for New Drug in Korea

Myelodysplastic Syndrome

Korea, Republic of
BioMérieux

Completed

VIDAS® NEPHROCLEAR Reference Interval Study

Healthy

United States
Technische Universität Dresden
Merck Sharp & Dohme LLC

Recruiting

MRD-guided Treatment in NPM1mut AML Patients (PEMAZA)

Acute Myeloid Leukemia

Germany
Zhujiang Hospital

Recruiting

Single Arm Study of Post-transplant Azacitidine and Chidamide for Prevention of Acute Myelogenous Leukemia Relapse

Leukemia, Myeloid, Acute

China
Bioniche Pharma USA LLC

Completed

Bioequivalence Study of Azacitidine for Injection in Myelodysplastic Syndrome (MDS) Patients

Myelodysplastic Syndrome

United States, France
Washington University School of Medicine
National Cancer Institute (NCI); National Institutes of Health (NIH); The Foundation...

Terminated

Azacitidine in Patients Undergoing Matched Unrelated Stem Cell Transplantation

Myelodysplastic Syndromes | Leukemia, Myeloid, Acute | Precursor Cell Lymphoblastic Leukemia-Lymphoma

United States
American Regent, Inc.

Completed

Bioequivalence Trial of Luitpold Azacitidine Versus Vidaza® in Patients With Myelodysplastic Syndrome, Myelofibrosis, Chronic Myeloid Leukemia or Chronic Lymphocytic Leukemia

Myelofibrosis | Chronic Lymphocytic Leukemia | Chronic Myeloid Leukemia | Myelodysplastic Syndrome

United States
University of California, San Francisco
Hellman Foundation

Completed

Donor Lymphocyte Infusion With Azacitidine to Prevent Hematologic Malignancy Relapse After Stem Cell Transplantation

Juvenile Myelomonocytic Leukemia | Myelodysplastic Syndrome | Acute Myelogenous Leukemia | Acute Lymphoid Leukemia

United States
University of Utah
Celgene

Completed

A Study of 5-Azacitidine (Vidaza®) in Patients With Chronic Myelomonocytic Leukemia

Chronic Myelomonocytic Leukemia

United States
Institut de Recherches Internationales Servier

Active, not recruiting

Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Participants With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation (AGILE)

Leukemia, Myeloid, Acute | Untreated AML | Newly Diagnosed Acute Myeloid Leukemia (AML) | AML Arising From Myelodysplastic Syndrome (MDS)

Spain, United States, France, Korea, Republic of, Taiwan, Australia, Canada, Germany, China, Italy, Austria, Czechia, Poland, Japan, United Kingdom, Russian Federation, Netherlands, Brazil, Israel, Mexico
Mirati Therapeutics Inc.

Terminated

MGCD0103 Administered in Combination With Azacitidine (Vidaza®) to Subjects With Relapsed or Refractory Hodgkin or Non-Hodgkin Lymphoma

Hodgkin Lymphoma | Non-Hodgkin Lymphoma (Follicular or Large Diffuse B-cell Lymphoma or Mantle Cell Lymphoma)

United States
H. Lee Moffitt Cancer Center and Research Institute
Bristol-Myers Squibb

Active, not recruiting

Nivolumab or Nivolumab and Azacitidine in Patients With Recurrent, Resectable Osteosarcoma

Sarcoma | Osteosarcoma | Osteosarcoma Recurrent | Osteosarcoma in Children

United States
Yale University

Completed

Window Trial 5-aza in HNSCC, T-tare

Head and Neck Squamous Cell Carcinoma

United States
French Innovative Leukemia Organisation
Celgene Corporation

Completed

Elderly Patients With Acute Myeloid Leukemia (AML), Maintenance Phase After Complete Remission (CR)

Acute Myeloid Leukemia

France
Mikkael Sekeres MD
National Cancer Institute (NCI)

Completed

Lenalidomide and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndromes

Myelodysplastic Syndromes | Leukemia

United States
Groupe Francophone des Myelodysplasies
Roche Pharma AG; Celgene Corporation

Completed

Azacitidine Combined to Epoetin Beta in International Prognostic Scoring System (IPSS) Low-risk and Intermediate-1 Myelodysplastic Syndrome (MDS) Patients, Resistant to Erythropoetin-stimulating Agents (ESA)

Myelodysplastic Syndromes

France
Associazione Qol-one

Completed

Efficacy of 5-Aza for Post-Remission Therapy of Acute Myeloid Leukemia (AML) in Elderly Patients

Acute Myeloid Leukemia

Italy
Sidney Kimmel Comprehensive Cancer Center at Johns...
Merck Sharp & Dohme LLC

Completed

Study of Azacitidine in Combination With Pembrolizumab in R/R AML Patients and in Newly Diagnosed Older Patients

Acute Myeloid Leukemia

United States
New Mexico Cancer Care Alliance

Completed

A Phase 1 Protocol of 5-Azacytidine and Erlotinib in Advanced Solid Tumor Malignancies

Advanced Solid Tumor Malignancies

United States
Groupe Francophone des Myelodysplasies
EpiCept Corporation

Withdrawn

Azacitidine With or Without Ceplene/Interleukin-2 in Patients With Higher Risk Myelodysplastic Syndromes

Myelodysplastic Syndromes

France
ConvaTec Inc.

Completed

Vitala 12 Hour Wear Test With Convex Products

End Colostomy

United States
Materia Medica Holding

Completed

Study on Efficacy and Safety of Divaza in Patients With Chronic Cerebral Ischemia and Cognitive Disorders (DIAMANT)

Chronic Cerebral Ischemia
University of Utah
Celgene Corporation

Completed

A Phase I/II Clinical Trial of Vidaza With Abraxane in Patients With Advanced/Metastatic Solid Tumors and Breast Cancer (VA)

Advanced or Metastatic Solid Tumors | Advanced or Metastatic Breast Cancer

United States
Sun Yat-sen University

Recruiting

Study of Chidamide as a Single-agent Treatment for Patients With Relapse or Refractory B-NHL

Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma (NHL)

China
Guangdong Provincial People's Hospital

Unknown

Chidamide for Refractory/Relapsed Peripheral T Cell Lymphoma

Peripheral T Cell Lymphoma

China
Nordic MDS Group

Unknown

The Efficacy of Azacitidine +/- Lenalidomide in High-risk Myelodysplastic Syndrome (MDS)and Acute Myeloid Leukemia (AML) With Del(5q).

Myelodysplastic Syndrome | Acute Myelogenous Leukemia

Sweden
University of Washington

Completed

Social Media for ART Adherence and Retention in Adolescents and Young Adults: the Vijana-SMART Study

Depression | Adherence, Medication | HIV-1-infection

Kenya
Materia Medica Holding

Completed

Clinical Trial of Efficacy and Safety of Divaza for Adjustment of Oxidative Disorders in Patients With Cerebral Atherosclerosis

Cerebral Atherosclerosis

Russian Federation
University of Illinois at Chicago

Recruiting

BRE-04: Window of Opportunity Trial of Preoperative Low Dose Azacitidine in High-Risk Early Stage Breast Cancer (BRE-04)

Breast Cancer Female | Breast Cancer Invasive

United States
Seoul St. Mary's Hospital
Celgene Corporation

Unknown

5 Day Versus 7 Day Azacitidine in Lower Risk Myelodysplastic Syndrome

Myelodysplastic Syndrome

Korea, Republic of
Incyte Corporation

Terminated

Study of INCB053914 in Subjects With Advanced Malignancies

Solid Tumors

United States
Weill Medical College of Cornell University
Celgene Corporation

Completed

Epigenetic Priming Using Azacitidine With Neoadjuvant Chemotherapy for Resectable Esophageal Cancer (VEOX)

Esophageal Cancer | Malignant Neoplasm of Cardio-esophageal Junction of Stomach

United States
Groupe Francophone des Myelodysplasies

Completed

Intensified Azacitidine in High Risk Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndrome

France
Celgene

Completed

Study With Azacitidine in Pediatric Subjects With Newly Diagnosed Advanced Myelodysplastic Syndrome (MDS) and Juvenile Myelomonocytic Leukemia (JMML)

Leukemia, Myelomonocytic, Juvenile | Myelodysplastic Syndrome

Spain, Germany, Italy, United Kingdom, Belgium, France, Denmark, Netherlands, Sweden, Switzerland, Austria, Czechia, Ireland
M.D. Anderson Cancer Center
Celgene Corporation

Completed

Ph II Study of Azacitidine in Myelofibrosis

Myelofibrosis

United States
University of Miami

Terminated

A Phase I/II Study of Azacitidine, Docetaxel, and Prednisone for Metastatic Prostate Cancer Patients

Pain | Prostate Cancer

United States
Peking University
Peking University International Hospital; Hebei Medical University Fourth Hospital

Unknown

Chidamide Maintenance After Autologous Hematopoietic Stem Cell Transplantation for Relapsed, Refractory or High-risk Lymphoma

Experimental Tumor

China
Dong mei

Unknown

Chidamide for Advanced Cephalic and Cervical Adenocystic Carcinoma: Evaluation of Efficiency and Safety

Adenocystic Carcinoma

China
Patrick Stiff

Recruiting

Vidaza and Valproic Acid Post Allogeneic Transplant for High Risk AML and MDS

Myelodysplastic Syndrome MDS | Acute Myelogenous Leukemia AML

United States
Innovent Biologics (Suzhou) Co. Ltd.

Suspended

A Study Evaluating the Safety and Efficacy of IBI188 in Combination With AZA in Subjects With Newly Diagnosed MDS

MDS

United States
Kansas City Veteran Affairs Medical Center

Unknown

Trial With Azacitidine in Newly Diagnosed Acute Myelogenous Leukemia (AML) Veterans Administration (VA) Elderly Patients Not Eligible for Standard Induction Therapy

Acute Myeloid Leukemia | Elderly

United States
Washington University School of Medicine
Genzyme, a Sanofi Company

Completed

A Phase I Study Of Thymoglobulin In Patients With Relapsed Or Refractory Multiple Myeloma

Relapsed Or Refractory Multiple Myeloma

United States

Search clinical trials for: Vidaza®

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Türkiye

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations